What is TherapeuticsMD, Inc. (TXMD)'s fair-value range?

EvidInvest reads TherapeuticsMD, Inc. (TXMD)'s market price back into the assumptions behind it — the implied P/E, growth rate and cash yield — using its latest filed financials, then lets you set your own. See the full DCF, Graham number, EPV and multiple-based methods at https://evidinvest.com/valuation/TXMD.

How is TherapeuticsMD, Inc. (TXMD)'s fair value calculated?

TherapeuticsMD, Inc. (TXMD)'s fair value is computed with several independent methods — a discounted cash flow (DCF) model, the Graham number, earnings power value (EPV), and valuation multiples (PE, EV/EBITDA, P/S, P/B) benchmarked against its industry — using data from SEC filings.

What is TherapeuticsMD, Inc. (TXMD)'s PE ratio versus its industry?

EvidInvest shows TherapeuticsMD, Inc. (TXMD)'s current and historical PE ratio alongside its sector and industry averages, so you can see whether the stock trades at a premium or discount to peers. Full breakdown at https://evidinvest.com/valuation/TXMD.

Fair value · TherapeuticsMD, Inc. (TXMD) · updated 2026-09-13 · from 10-K FY2025

TherapeuticsMD trades at $2.16. That price implies a 13.2% free-cash-flow yield.

Cboe · delayed 15 min · as of 03:40 ET

Are those assumptions reasonable? Use TXMD’s filed growth history and the AI chat to decide, then set your own inputs below — the range you build is yours.

What the price implies

FCF yield: 13.2%

Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings. This price: Cboe · delayed 15 min · as of 03:40 ET.

Set your own assumptions ↓See how each method got its number Check another stock

The filing behind these numbers

TherapeuticsMD, Inc.

Revenue: $3.0M
Diluted EPS: $-0.05
Free cash flow: $2.4M; operating cash flow − capital expenditure
Diluted shares: 11.6M; weighted average

10-K FY2025 · fiscal year ended 2025-12-31 · filed 2026-03-30 · accession 0001213900-26-036515

Trailing-twelve-month EPS also uses the quarterly 10-Qs through Q2 FY2026 (filed 2026-08-11).

Open this filing on sec.gov

Valuation tool: build your own TXMD range

Fair Value Summary

Daily Price — TXMD

$2.16 +94.6% (1Y)

Range implied by today’s price2 of 7 methods

$3.00 – $4.67

Price $2.16

Bear $3.00Base $3.84Bull $4.67

Range with preset inputs

$5.51 – $5.51

Price $2.16

Bear $5.51Base $5.51Bull $5.51

Every method that could be solved backwards opens on the assumption today’s price makes, so the top range sits on the price — that is arithmetic, not a view. Change any input and it becomes yours.

We don’t tell you what TXMD is worth. Every tab OPENS on what today’s price implies for that method’s key assumption; you decide whether that assumption is reasonable — the growth matrix has TXMD’s filed history and the AI chat will reason it through with you — and the range you build is yours. Our presets are filed history and reference settings, never a recommendation.

Discounted cash flow

$2.16per share

0% below the $2.16 price

Your stage-1 FCF growth (-11.1%) matches the -11.1% the price implies — your value lands on today’s price.

Your inputs — two-stage free-cash-flow model

Implied by today’s price

At $2.16 the market implies a stage-1 FCF growth of -11.1%. (two-stage FCF model solved for stage-1 growth at 6.82% WACC)

Implied discount rate (holding growth): 6.8% · the WACC that makes the same model print the price

This tab opens on that number, so the value above is today’s price restated. Move the slider to what you find reasonable: the growth matrix shows what TXMD has actually filed, and the AI chat will reason it through with you.

Your inputs

Free cash flow grows at your stage-1 rate, then your stage-2 rate, then a terminal rate; everything is discounted at your WACC.

Stage-1 growth-11.1%preset 5.0%

Yearly free-cash-flow growth for the first stage. Starts below zero so a shrinking-cash-flow case — and the rate today’s price implies — can be set.

-20.0%110.0%

Stage-1 years5 yrs

How long stage-1 growth lasts.

1 yrs10 yrs

Stage-2 growth2.5%

Slower growth after stage 1, before the terminal phase.

-20.0%30.0%

Stage-2 years5 yrs

0 yrs10 yrs

Terminal growth2.5%

Growth forever after the two stages. Above ~3% is rarely justified.

0.0%5.0%

Discount rate (WACC)6.82%

The return you require. Default is the WACC EvidInvest computed for this company. Higher discount rate, lower value.

3.00%15.00%

Net debt ($M)Debt minus cash, from the balance sheet. Subtracted from enterprise value.

Starting FCF ($M)Latest free cash flow from the filing (operating cash flow minus capex).

Shares (M)Diluted shares, from the filing.

Year by year (two-stage model, $M)

PV explicit $9M · PV terminal $15M · EV $25M · equity $26M

Year	Stage	FCF	Present value
1	Stage 1	$2M	$2M
2	Stage 1	$2M	$1M
3	Stage 1	$1M	$1M
4	Stage 1	$1M	$1M
5	Stage 1	$1M	$1M
6	Stage 2	$1M	$1M
7	Stage 2	$1M	$1M
8	Stage 2	$1M	$1M
9	Stage 2	$1M	$1M
10	Stage 2	$1M	$1M

Inputs from the filing

Free cash flow: $3.1M; sum of the last four quarters
EBIT: $-4.4M; latest annual
Shares: 11.6M
Total debt: $6.1M
Cash: $7.5M
Net debt: $-1.4M; debt − cash

10-K FY2025 · period ended 2025-12-31 · filed 2026-03-30 · accession 0001213900-26-036515 · sec.gov

Prefer a blank slate with reverse DCF? Open the standalone DCF / reverse DCF for TXMD

Loading history...

Download the full TXMD valuation report (PDF) — free

DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.

TherapeuticsMD trades at $2.16. That price implies a 13.2% free-cash-flow yield.

The filing behind these numbers

Valuation tool: build your own TXMD range

Daily Price — TXMD

Range implied by today’s price2 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on TXMD

Compare with peers

Explore

Valuation tool: build your own TXMD range

Daily Price — TXMD

Range implied by today’s price2 of 7 methods

Range with preset inputs

Your inputs

Year by year (two-stage model, $M)

More on TXMD

Compare with peers

Explore